Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05140382 · OUTCOME

Progression-free Survival (PFS)

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL · Source last updated 2024-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
From Screening (Day -30 to Day-1) until disease progression or survival until death (26 months).

What was measured

Progression-free survival is defined as the time from the date of first dose to documented disease progression, or death from any cause, whichever occurs first.

Analysis population: Full analysis set included all participants who received any amount of any study intervention.

Groups in this outcome

Cohort 1 Non-NK PTCL

Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.

Cohort 2 NK PTCL

Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.

Cohort 3 cHL

Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 1 Non-NK PTCL31
Cohort 2 NK PTCL2
Cohort 3 cHL19

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cohort 1 Non-NK PTCL1.8Not reported1.512.17Not reported
Cohort 2 NK PTCL0.7Not reported0.66NAHere, "NA" indicates that higher limit of 95% CI could not be evaluated due to smaller number of participants.
Cohort 3 cHL1.9Not reported1.644.11Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.51
        upper Limit
        2.17
        value
        1.8
      2. comment
        Here, "NA" indicates that higher limit of 95% CI could not be evaluated due to smaller number of participants.
        group Id
        OG001
        lower Limit
        0.66
        upper Limit
        NA
        value
        0.7
      3. group Id
        OG002
        lower Limit
        1.64
        upper Limit
        4.11
        value
        1.9
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    2. group Id
      OG001
      value
      2
    3. group Id
      OG002
      value
      19
    units
    Participants
description
Progression-free survival is defined as the time from the date of first dose to documented disease progression, or death from any cause, whichever occurs first.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
    id
    OG000
    title
    Cohort 1 Non-NK PTCL
  2. description
    Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
    id
    OG001
    title
    Cohort 2 NK PTCL
  3. description
    Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.
    id
    OG002
    title
    Cohort 3 cHL
param Type
MEDIAN
population Description
Full analysis set included all participants who received any amount of any study intervention.
reporting Status
POSTED
time Frame
From Screening (Day -30 to Day-1) until disease progression or survival until death (26 months).
title
Progression-free Survival (PFS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice